<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="leukodys-ov" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">leukodys-ov</book-part-id>
      <title-group>
        <title>Leukodystrophy Overview</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vanderver</surname>
            <given-names>Adeline</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Children's Hospital of Philadelphia<break/>Philadelphia, Pennsylvania</aff>
          <email>vandervera@email.chop.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tonduti</surname>
            <given-names>Davide</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Child Neurology and Psychiatry, IRCCS C<break/>Mondino Institute of Neurology Foundation<break/>Pavia, Italy</aff>
          <email>davidetondu@hotmail.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schiffmann</surname>
            <given-names>Raphael</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Institute of Metabolic Disease<break/>Baylor Research Institute<break/>Dallas, Texas</aff>
          <email>p15099@baylorhealth.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schmidt</surname>
            <given-names>Johanna</given-names>
          </name>
          <degrees>MPH, MGC, CGC</degrees>
          <aff>Department of Neurology &#x00026; Center for Genetic Medicine Research<break/>Children's National Medical Center<break/>Washington, DC</aff>
          <email>jloewens@childrensnational.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>van der Knaap</surname>
            <given-names>Marjo S</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Child Neurology<break/>Vrije Universiteit Medical Center<break/>Amsterdam, Netherlands</aff>
          <email>ms.vanderknaap@vumc.nl</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>6</day>
          <month>2</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="lns" document-type="chapter">Lesch-Nyhan Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="lbsl" document-type="chapter">Leukoencephalopathy with Brain Stem and Spinal Cord Involvement and Lactate Elevation</related-object>
      <abstract id="leukodys-ov.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Leukodystrophies are heritable myelin disorders affecting the white matter of the central nervous system with or without peripheral nervous system myelin involvement. Involvement of the white matter tracts almost universally leads to motor involvement that manifests as hypotonia in early childhood and progresses to spasticity over time. This may lead to variable motor impairment, from mild spastic diplegia to severe spastic quadriplegia that limits purposeful movement. In addition, motor dysfunction is likely to significantly impair vital functions including swallowing, chewing, and (in some cases) respiration. Other findings that vary by disorder include extrapyramidal movement disorders (e.g., dystonia and/or dyskinesias), ataxia, seizures, and delay in cognitive development or change in cognitive function over time.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Establishing the specific leukodystrophy present in a given individual usually involves:</p>
          <list list-type="bullet">
            <list-item>
              <p>Obtaining a medical history and detailed family history</p>
            </list-item>
            <list-item>
              <p>Performing a physical examination and neurologic examination</p>
            </list-item>
            <list-item>
              <p>Review of brain MRI findings:</p>
              <list list-type="bullet">
                <list-item>
                  <p>T<sub>2</sub>-weighted hyperintensity in the white matter is the MRI finding required for diagnosis of a leukodystrophy.</p>
                </list-item>
                <list-item>
                  <p>T<sub>1</sub>-weighted signal may be variable: iso- or hyper- intense T<sub>1</sub>-weighted signal is consistent with a hypomyelinating leukodystrophy; hypointense T<sub>1</sub>-weighted signal is consistent with a demyelinating leukodystrophy.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Performing specialized laboratory testing, often including molecular genetic testing (either stepwise single gene testing or use of a multi-gene panel targeted to the leukodystrophies).</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Leukodystrophies with an identified genetic cause may be inherited in an autosomal dominant manner, an autosomal recessive manner, or an X-linked recessive manner. Genetic counseling regarding risk to family members depends on accurate diagnosis, determination of the mode of inheritance in each family, and results of molecular genetic testing. Prenatal testing for pregnancies at increased risk is possible for some types of leukodystrophy if the pathogenic variant(s) in the family are known. Many leukodystrophies are still without an identified genetic cause; once a genetic cause is identified, other inheritance patterns may emerge.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment is symptomatic and ideally occurs in a multidisciplinary setting by specialists experienced in the care of persons with a leukodystrophy. Pharmacologic agents are used to manage muscle tone and block neuronal signaling to muscle (chemodenervation). Intensive physical therapy is used to improve mobility and function. Pharmacologic treatment of dystonia and dyskinesias may result in significant functional improvement. Treatment of ataxia, seizures, and cognitive issues is provided in the usual manner, depending on the needs of the individual.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> In a few leukodystrophies primary disease manifestations can be prevented by hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation (BMT) early in the disease course.</p>
          <p><italic toggle="yes">Surveillance:</italic> Routine assessment of growth and nutritional status; physical examination and/or serial x-rays of the hips and spine to monitor for orthopedic complications; and routine history re signs and symptoms of seizures.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Mild head injuries and infection as these may exacerbate disease manifestations.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> When primary prevention of a leukodystrophy is possible (e.g., by HSCT or BMT), it is appropriate to offer testing to asymptomatic at risk relatives who would benefit from early diagnosis and consideration of early treatment.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="leukodys-ov.Definition_of_Leukodystrophy">
        <title>Definition of Leukodystrophy</title>
        <p>The term leukodystrophy, as well as associated terms such as dysmyelination, demyelination, and leukoencephalopathy, are applied to a broad group of disorders.</p>
        <p>In this <italic toggle="yes">GeneReview</italic> chapter, the following definition is used: Leukodystrophies are heritable myelin disorders affecting the white matter of the central nervous system with or without peripheral nervous system myelin involvement.</p>
        <p>Leukodystrophies share the following findings:</p>
        <list list-type="bullet">
          <list-item>
            <p>Abnormalities of the glial cell or myelin sheath, such that neuropathology &#x02013; when known &#x02013; is characterized primarily by involvement of oligodendrocytes, astrocytes, and other non-neuronal cell types. Of note, in many leukodystrophies the underlying disease mechanism is unknown.</p>
          </list-item>
          <list-item>
            <p>MRI findings (see <xref ref-type="fig" rid="leukodys-ov.F1">Figure 1</xref>)</p>
            <list list-type="bullet">
              <list-item>
                <p>T<sub>2</sub>-weighted hyperintensity in the white matter must be present.</p>
              </list-item>
              <list-item>
                <p>T<sub>1</sub>-weighted signal may be variable: iso- or hyperintense T<sub>1</sub>-weighted signal is consistent with a hypomyelinating leukodystrophy; hypointense T<sub>1</sub>-weighted signal is consistent with a demyelinating leukodystrophy.</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="leukodys-ov.Clinical_Manifestations_of_L">
        <title>Clinical Manifestations of Leukodystrophies</title>
        <p>A number of leukodystrophies that meet the definition used in this <italic toggle="yes">GeneReview</italic> chapter are listed in <xref ref-type="table" rid="leukodys-ov.T.leukodystrophies_meeting_s">Table 1</xref>.</p>
        <p>Involvement of the white matter tracts almost universally leads to motor involvement that manifests as hypotonia in early childhood and progresses to spasticity over time. This may lead to variable motor impairment, from mild spastic diplegia to severe spastic quadriplegia that limits purposeful movement. In addition, motor dysfunction is likely to significantly impair vital functions including swallowing, chewing and (in some cases) respiration. Spasticity may result in orthopedic complications such as scoliosis and large joint luxation.</p>
        <p>Significant pyramidal dysfunction (i.e., spasticity) may sometimes mask or overshadow the presence of extrapyramidal movement disorders such as dystonia and/or dyskinesias. For example, in <related-object link-type="booklink" source-id="gene" document-id="thctd" document-type="chapter">MCT8-specific thyroid hormone cell transporter deficiency</related-object> dystonia is a prominent finding.</p>
        <p>Ataxia is a predominant finding in some leukodystrophies and can be disabling; for example, <related-object link-type="booklink" source-id="gene" document-id="cach" document-type="chapter">childhood ataxia with central nervous system hypomyelination/vanishing white matter</related-object> (CACH/VWM) and <related-object link-type="booklink" source-id="gene" document-id="pol3-leuk" document-type="chapter">hypomyelination with hypogonadotropic hypogonadism and hypodontia</related-object> (4H syndrome).</p>
        <p>Seizures are an often late manifestation of leukodystrophies, with the exception of rare leukodystrophies (e.g., <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object>) in which they are often a presenting feature.</p>
        <p>Delay in cognitive development or change in cognitive function over time, while far less pronounced than motor dysfunction, can be common in the child or adult with leukodystrophy. Because progressive loss of cognitive function is slow in the majority of leukodystrophies, dementia is not an early feature.</p>
      </sec>
      <sec id="leukodys-ov.Prevalence_of_Leukodystrophi">
        <title>Prevalence of Leukodystrophies</title>
        <p>Epidemiologic data on the frequency of leukodystrophies overall are limited [<xref ref-type="bibr" rid="leukodys-ov.REF.heim.1997.475">Heim et al 1997</xref>, <xref ref-type="bibr" rid="leukodys-ov.REF.bonkowsky.2010.718">Bonkowsky et al 2010</xref>]. Furthermore, it is difficult to infer from these studies with any certainty the relative frequency of specific leukodystrophies.</p>
        <p>Better information on prevalence is available for leukodystrophies that are seen regularly in specialized clinics and in general child neurology practices; these include <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object> [<xref ref-type="bibr" rid="leukodys-ov.REF.van_der_knaap.1999.121">van der Knaap et al 1999</xref>], <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object> [<xref ref-type="bibr" rid="leukodys-ov.REF.bezman.2001.512">Bezman et al 2001</xref>] and <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">metachromatic leukodystrophy</related-object>.</p>
        <p>As disorders such as certain adult-onset-only leukodystrophies and hypomyelinating leukodystrophies become better defined, the heterogeneity of the inherited white matter disorders is increasingly recognized.</p>
        <p>It is important to note that in approximately 50% of individuals with a white matter disorder the specific etiology is unknown because of the heterogeneity and complexity of these disorders [<xref ref-type="bibr" rid="leukodys-ov.REF.schiffmann.2009.750">Schiffmann &#x00026; van der Knaap 2009</xref>].</p>
      </sec>
      <sec id="leukodys-ov.Differential_Diagnosis_of_Le">
        <title>Differential Diagnosis of Leukodystrophies</title>
        <p><bold>Hereditable disorders with significant white matter involvement</bold> that are not leukodystrophies are listed in <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> (pdf); they include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Inherited vasculopathies</bold> that can result in white matter signal abnormalities, including inherited abnormalities of the vessel wall, such as <related-object link-type="booklink" source-id="gene" document-id="cadasil" document-type="chapter">CADASIL</related-object> and <related-object link-type="booklink" source-id="gene" document-id="col4a1-dis" document-type="chapter"><italic toggle="yes">COL4A1</italic></related-object> and <italic toggle="yes">COL4A2-</italic>related disorders, which can give rise to multifocal white matter abnormalities. In end-stage disease, confluent signal abnormalities in the periventricular and deep white matter may be seen, typically with multifocal abnormalities in central gray matter structures and brain stem. Because these are not primary glial cell disorders, they are not considered to be leukodystrophies.</p>
          </list-item>
          <list-item>
            <p><bold>CNS diseases</bold>
<bold>with primary involvement of neurons in the cerebral cortex or other gray matter structures</bold> (in which brain MRI also reveals significant white matter abnormalities). Typical findings are significant encephalopathy and seizures.</p>
            <list list-type="bullet">
              <list-item>
                <p>The infantile variants of disorders like GM1 gangliosidosis, <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">GM2 gangliosidosis</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="ncl" document-type="chapter">neuronal ceroid-lipofuscinosis</related-object> may have significant white matter abnormalities because the disease, which is primarily neuronal, also disrupts the normal process of myelination. Later-onset variants of these disorders eventually affect the cerebral white matter; mild signal abnormalities are related to Wallerian degeneration with loss of axons and myelin.</p>
              </list-item>
              <list-item>
                <p>In other disorders, such as <related-object link-type="booklink" source-id="gene" document-id="thctd" document-type="chapter">MCT8-specific thyroid hormone cell transporter deficiency</related-object>, myelination can be extremely delayed but progress over time to become almost complete.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Inborn errors of metabolism</bold> with significant secondary white matter abnormalities, such as organic acidemias, disorders of amino acid metabolism and many others. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> (pdf).</p>
          </list-item>
          <list-item>
            <p><bold>Disorders that affect both white and gray matter.</bold> Examples in which both white matter injury and gray matter lesions are observed include mitochondrial disorders such as <related-object link-type="booklink" source-id="gene" document-id="melas" document-type="chapter">MELAS</related-object> (<italic toggle="yes">m</italic>itochondrial <italic toggle="yes">e</italic>ncephalopathy with <italic toggle="yes">l</italic>actic <italic toggle="yes">a</italic>cidosis and <italic toggle="yes">s</italic>eizures), <related-object link-type="booklink" source-id="gene" document-id="alpers" document-type="chapter"><italic toggle="yes">POLG</italic>-related disorders</related-object>, and familial <related-object link-type="booklink" source-id="gene" document-id="hlh" document-type="chapter">hemophagocytic lymphohistiocytosis</related-object>.</p>
          </list-item>
        </list>
        <p><bold>Other disorders with significant white matter</bold>
<bold>involvement</bold> include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acquired CNS myelin disorders</bold> that result in demyelination, such as multiple sclerosis and those of <bold>infectious, post-infectious, and autoimmune</bold> etiology. Although not heritable in a Mendelian fashion, some of these disorders may have multifactorial etiologies that include a genetic predisposition.</p>
          </list-item>
          <list-item>
            <p>Disorders such as acute disseminated encephalomyelitis, multiple sclerosis, and neuromyelitis optica typically differ from heritable white matter disorders by their abrupt onset and multiphasic presentations. Brain MRI abnormalities are also more likely to be multifocal and patchy [<xref ref-type="bibr" rid="leukodys-ov.REF.schiffmann.2009.750">Schiffmann &#x00026; van der Knaap 2009</xref>], with variation or even improvement over time and with treatment.</p>
          </list-item>
          <list-item>
            <p><bold>Toxic injuries</bold> of the myelin, such as those seen in heroin abuse or methotrexate-related toxicity</p>
          </list-item>
          <list-item>
            <p><bold>Central nervous system injury</bold>, particularly in the perinatal period, which can result in significant white matter signal abnormalities that are typically irregular, and may result in loss of white matter volume</p>
          </list-item>
          <list-item>
            <p>Non-genetic vascular insults</p>
          </list-item>
        </list>
      </sec>
      <sec id="leukodys-ov.Evaluation_Strategy_for_an_I">
        <title>Evaluation Strategy for an Individual with a Leukodystrophy</title>
        <p>Once a leukodystrophy is considered in an individual, the following approach can be used to determine the specific leukodystrophy to aid in discussions of prognosis and genetic counseling.</p>
        <p>Establishing the specific leukodystrophy (<xref ref-type="table" rid="leukodys-ov.T.leukodystrophies_meeting_s">Table 1</xref>) present in a given individual usually involves obtaining a medical history and detailed family history; performing a physical examination and neurologic examination; review of brain MRI findings; and specialized laboratory testing, often including molecular genetic testing.</p>
        <p>Note: Adherence to the diagnostic approach discussed in this section notwithstanding, a specific diagnosis cannot be established in a clinical (i.e., not research) setting in a significant number of individuals with a leukodystrophy [<xref ref-type="bibr" rid="leukodys-ov.REF.van_der_knaap.1999.121">van der Knaap et al 1999</xref>, <xref ref-type="bibr" rid="leukodys-ov.REF.schiffmann.2009.750">Schiffmann &#x00026; van der Knaap 2009</xref>].</p>
        <sec id="leukodys-ov.Medical_History">
          <title>Medical History</title>
          <p>A history of certain clinical features may be helpful in identifying a specific leukodystrophy; however, in the majority of cases, only nonspecific loss of function (primarily motor) occurs and medical history alone does not provide insight into a specific diagnosis.</p>
          <p>In the hypomyelinating leukodystrophies helpful diagnostic clues may, for example, be the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Congenital cataract: <related-object link-type="booklink" source-id="gene" document-id="hypo-mcc" document-type="chapter">hypomyelination and congenital cataract</related-object> (HCC)</p>
            </list-item>
            <list-item>
              <p>Hypodontia and/or hypogonadotropic hypogonadism: <related-object link-type="booklink" source-id="gene" document-id="pol3-leuk" document-type="chapter"><italic toggle="yes">POLR3</italic>-related leukodystrophy</related-object></p>
            </list-item>
            <list-item>
              <p>Severe seizures: <related-object link-type="booklink" source-id="gene" document-id="issd" document-type="chapter">sialic acid storage disorders</related-object></p>
            </list-item>
          </list>
          <p>In the demyelinating leukodystrophies helpful diagnostic clues may, for example, be the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Recurrent vomiting: <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object></p>
            </list-item>
            <list-item>
              <p>Adrenal dysfunction: <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object> (X-ALD)</p>
            </list-item>
            <list-item>
              <p>Early-onset autonomic dysfunction: <related-object link-type="booklink" source-id="gene" document-id="lad-ad" document-type="chapter">AD adult-onset leukodystrophy</related-object> (ADLD)</p>
            </list-item>
            <list-item>
              <p>Chronic cerebrospinal fluid lymphocytosis or (more often) recurrent &#x0201c;aseptic meningitis&#x0201d;: <related-object link-type="booklink" source-id="gene" document-id="ags" document-type="chapter">Aicardi-Gouti&#x000e8;res syndrome</related-object></p>
            </list-item>
            <list-item>
              <p>Abrupt loss of function after a fever or fall: <related-object link-type="booklink" source-id="gene" document-id="cach" document-type="chapter">childhood ataxia with central nervous system hypomyelination/vanishing white matter</related-object> (and possibly other leukodystrophies)</p>
            </list-item>
          </list>
        </sec>
        <sec id="leukodys-ov.Family_History">
          <title>Family History</title>
          <p>A detailed three-generation family history focusing on individuals with hypotonia, spasticity, dystonia, seizures, ataxia, and/or delay in cognitive development or change in cognitive function over time.</p>
          <list list-type="bullet">
            <list-item>
              <p>Because most leukodystrophies are autosomal recessive, special attention to parental <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/consanguinity/"><underline>consanguinity</underline></ext-link> and medical problems in sibs is warranted.</p>
            </list-item>
            <list-item>
              <p>Evaluation of relatives and/or review of their medical records may be needed.</p>
            </list-item>
          </list>
        </sec>
        <sec id="leukodys-ov.Physical_Examination_and_Neu">
          <title>Physical Examination and Neurologic Examination</title>
          <p>In most instances physical findings do not suggest a specific diagnosis; however, certain findings may direct the reader to further explore specific underlying etiologies:</p>
          <list list-type="bullet">
            <list-item>
              <p>Macrocephaly; see <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Tables5-6.pdf" content-type="local-data">Table 6</inline-supplementary-material> (pdf)</p>
            </list-item>
            <list-item>
              <p>Abnormal dentition: <related-object link-type="booklink" source-id="gene" document-id="pol3-leuk" document-type="chapter"><italic toggle="yes">POLR3</italic>-related leukodystrophy</related-object> or oculodentodigital dysplasia (ODDD)</p>
            </list-item>
            <list-item>
              <p>Palatal myoclonus in adults: <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object></p>
            </list-item>
            <list-item>
              <p>Xanthomas: <related-object link-type="booklink" source-id="gene" document-id="ctx" document-type="chapter">cerebrotendinous xanthomatosis</related-object> (CTX)</p>
            </list-item>
            <list-item>
              <p>Abnormalities of skin pigmentation: <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object> (X-ALD)</p>
            </list-item>
            <list-item>
              <p>Ichthyosis: Sj&#x000f6;gren-Larsson syndrome</p>
            </list-item>
            <list-item>
              <p>Vascular retinal abnormalities: cerebroretinal microangiopathy w/calcifications &#x00026; cysts (CRMCC)</p>
            </list-item>
            <list-item>
              <p>Cherry red spot on retinal examination: disorders such as GM1 and <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">GM2 gangliosidosis</related-object></p>
            </list-item>
          </list>
        </sec>
        <sec id="leukodys-ov.Brain_MRI_Findings">
          <title>Brain MRI Findings</title>
          <sec id="leukodys-ov.Step_1">
            <title>Step 1</title>
            <p>Establish whether the pattern of brain MRI abnormalities is consistent with a hypomyelinating leukodystrophy or a demyelinating leukodystrophy (<xref ref-type="fig" rid="leukodys-ov.F1">Figure 1</xref>) [<xref ref-type="bibr" rid="leukodys-ov.REF.van_der_knaap.1999.121">van der Knaap et al 1999</xref>, <xref ref-type="bibr" rid="leukodys-ov.REF.van_der_knaap.2005">van der Knaap &#x00026; Valk 2005</xref>, <xref ref-type="bibr" rid="leukodys-ov.REF.schiffmann.2009.750">Schiffmann &#x00026; van der Knaap 2009</xref>].</p>
          </sec>
          <sec id="leukodys-ov.Step_2">
            <title>Step 2</title>
            <p>Within the hypomyelinating and demyelinating leukodystrophies, determine if patterns of involvement suggest specific diagnoses.</p>
            <p><bold>Hypomyelinating leukodystrophy.</bold> Note specific patterns on neuroimaging that include the following (<xref ref-type="fig" rid="leukodys-ov.F2">Figure 2</xref>):</p>
            <list list-type="bullet">
              <list-item>
                <p>Improvement of myelination over time (e.g., as seen in <related-object link-type="booklink" source-id="gene" document-id="thctd" document-type="chapter">MCT8-specific thyroid hormone cell transporter deficiency</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F2">Figure 2A&#x02192;B</xref>)</p>
              </list-item>
              <list-item>
                <p>Severe atrophy of cortical gray matter (variably seen in primary neuronal disorders as well as a limited number of classic leukodystrophies; see <xref ref-type="fig" rid="leukodys-ov.F2">Figure 2C</xref>)</p>
              </list-item>
              <list-item>
                <p>Persistent hypomyelination without atrophy of cortical gray matter (e.g., in <related-object link-type="booklink" source-id="gene" document-id="pmd" document-type="chapter">Pelizaeus-Merzbacher disease</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F2">Figure 2D</xref>)</p>
              </list-item>
              <list-item>
                <p>Cerebellar atrophy (e.g., in <related-object link-type="booklink" source-id="gene" document-id="pol3-leuk" document-type="chapter"><italic toggle="yes">POLR3</italic>-related leukodystrophy</related-object> [4H syndrome]; see <xref ref-type="fig" rid="leukodys-ov.F2">Figure 2E</xref>)</p>
              </list-item>
              <list-item>
                <p>Basal ganglia involvement (e.g., in HABC syndrome; see <xref ref-type="fig" rid="leukodys-ov.F2">Figure 2F</xref>)</p>
              </list-item>
            </list>
            <p>
              <bold>Demyelinating leukodystrophy</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Identify the region in which white matter abnormalities predominate.</p>
              </list-item>
              <list-item>
                <p>Distinguish confluent from multifocal lesions (<xref ref-type="fig" rid="leukodys-ov.F3">Figure 3</xref>):</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Confluent white matter lesions are extensive white matter abnormalities in significant portions of the brain, often affecting specific regions or tracts, although not necessarily perfectly symmetrically.</p>
                  </list-item>
                  <list-item>
                    <p>Multifocal white matter lesions are more discrete, often asymmetric and involving a limited area. Multifocal abnormalities have a specific differential diagnosis.</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <p>Specific patterns on neuroimaging in confluent disorders include (<xref ref-type="fig" rid="leukodys-ov.F4">Figure 4</xref>):</p>
            <list list-type="bullet">
              <list-item>
                <p>Diffuse cerebral involvement (e.g., as seen in <related-object link-type="booklink" source-id="gene" document-id="mlc" document-type="chapter">megalencephalic leukodystrophy with subcortical cysts</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4A</xref>)</p>
              </list-item>
              <list-item>
                <p>Frontal involvement (e.g., in <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4B</xref>)</p>
              </list-item>
              <list-item>
                <p>Parieto-occipital involvement (e.g. in <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4C</xref>)</p>
              </list-item>
              <list-item>
                <p>Temporal involvement (e.g., in <related-object link-type="booklink" source-id="gene" document-id="ags" document-type="chapter">Aicardi-Gouti&#x000e8;res syndrome</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4D</xref>)</p>
              </list-item>
              <list-item>
                <p>Subcortical involvement (e.g., in <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Kearns-Sayre syndrome</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4E</xref>)</p>
              </list-item>
              <list-item>
                <p>Periventricular involvement (e.g., in <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">metachromatic leukodystrophy</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4F</xref>)</p>
              </list-item>
              <list-item>
                <p>Brain stem involvement (e.g., in <related-object link-type="booklink" source-id="gene" document-id="apbd" document-type="chapter">adult polyglucosan body disease</related-object> with heterogeneous involvement of the brain stem; see <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4G</xref>)</p>
              </list-item>
              <list-item>
                <p>Cerebellar/cerebellar peduncle involvement (e.g., in <related-object link-type="booklink" source-id="gene" document-id="lad-ad" document-type="chapter">AD adult-onset leukodystrophy</related-object> (ADLD) with involvement of the middle cerebellar peduncles; see <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4H</xref>)</p>
              </list-item>
              <list-item>
                <p>Large, asymmetric lesions (e.g., in <related-object link-type="booklink" source-id="gene" document-id="hdls" document-type="chapter">hereditary diffuse leukoencephalopathy with spheroids</related-object> [HDLS]; <xref ref-type="fig" rid="leukodys-ov.F4">Figure 4I</xref>)</p>
              </list-item>
            </list>
            <p><bold>Diagnostic algorithm.</bold> For algorithms based on MRI findings, see <xref ref-type="fig" rid="leukodys-ov.F5">Figure 5</xref> (demyelinating and other conditions) and <xref ref-type="fig" rid="leukodys-ov.F6">Figure 6</xref> (hypomyelinating conditions) [<xref ref-type="bibr" rid="leukodys-ov.REF.schiffmann.2009.750">Schiffmann &#x00026; van der Knaap 2009</xref>].</p>
          </sec>
          <sec id="leukodys-ov.Step_3">
            <title>Step 3</title>
            <p>Look for the following associated features which, in addition to the pattern of findings on brain MRI, can assist in recognition of a specific leukodystrophy:</p>
            <list list-type="bullet">
              <list-item>
                <p>White matter rarefaction and cysts (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table3.pdf" content-type="local-data">Table 3</inline-supplementary-material>) seen on FLAIR imaging (e.g., in vanishing white matter disease: <related-object link-type="booklink" source-id="gene" document-id="cach" document-type="chapter">childhood ataxia with central nervous system hypomyelination/vanishing white matter</related-object>; <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7A</xref>)</p>
              </list-item>
              <list-item>
                <p>Calcium deposits and hemosiderin deposits (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table4.pdf" content-type="local-data">Table 4</inline-supplementary-material>) visible on CT, and not easily distinguishable on MRI (e.g., in <related-object link-type="booklink" source-id="gene" document-id="ags" document-type="chapter">Aicardi-Gouti&#x000e8;res syndrome</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7B</xref>)</p>
              </list-item>
              <list-item>
                <p>Contrast enhancement (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Tables5-6.pdf" content-type="local-data">Table 5</inline-supplementary-material>) on T<sub>1</sub>-weighted imaging within the abnormal white matter (e.g., in <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7C</xref>)</p>
              </list-item>
              <list-item>
                <p>Leukoencephalopathy with macrocephaly(<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Tables5-6.pdf" content-type="local-data">Table 6</inline-supplementary-material>)</p>
              </list-item>
              <list-item>
                <p>Cortical gray matter lesions (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table7.pdf" content-type="local-data">Table 7</inline-supplementary-material>) (e.g., in <related-object link-type="booklink" source-id="gene" document-id="alpers" document-type="chapter"><italic toggle="yes">POLG</italic>-related disorders</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7D</xref>)</p>
              </list-item>
              <list-item>
                <p>Cerebellar abnormalities (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table8.pdf" content-type="local-data">Table 8</inline-supplementary-material>) seen in the dentate nucleus (e.g., in L-2-hydroxyglutaric aciduria; see <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7E</xref>)</p>
              </list-item>
              <list-item>
                <p>Thinning of the corpus callosum (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table9.pdf" content-type="local-data">Table 9</inline-supplementary-material>), in particular, of the genu (e.g., in <related-object link-type="booklink" source-id="gene" document-id="spg11" document-type="chapter">hereditary spastic paraplegia 11</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7F</xref>)</p>
              </list-item>
              <list-item>
                <p>Non-calcifying basal ganglia lesions (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table10.pdf" content-type="local-data">Table 10</inline-supplementary-material>) (e.g., in <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7G</xref>, signal abnormality of the basal ganglia and frontal white matter)</p>
              </list-item>
              <list-item>
                <p>Brain stem involvement (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table11.pdf" content-type="local-data">Table 11</inline-supplementary-material>) (e.g., in <related-object link-type="booklink" source-id="gene" document-id="lad-ad" document-type="chapter">AD adult-onset leukodystrophy</related-object> (ADLD); see <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7H</xref>)</p>
              </list-item>
              <list-item>
                <p>Spinal cord involvement (<inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="leukodys-ov-Table12.pdf" content-type="local-data">Table 12</inline-supplementary-material>) (seen in many disorders, including <related-object link-type="booklink" source-id="gene" document-id="lbsl" document-type="chapter">LBSL</related-object>; see <xref ref-type="fig" rid="leukodys-ov.F7">Figure 7I</xref>, an example of involvement of tracts within the spinal cord)</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="leukodys-ov.Specialized_Laboratory_Testi">
          <title>Specialized Laboratory Testing (including Molecular Genetic Testing)</title>
          <p>If the findings on brain MRI are consistent with a specific leukodystrophy, consider biochemical or molecular genetic testing for that disorder (<xref ref-type="table" rid="leukodys-ov.T.leukodystrophies_meeting_s">Table 1</xref>). Note: Molecular genetic testing may be performed either as single gene testing in a stepwise fashion based on the information gained during the evaluation or, if available, as a multi-gene panel.</p>
          <table-wrap id="leukodys-ov.T.leukodystrophies_meeting_s" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Leukodystrophies Meeting Strict Diagnostic Criteria</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Name of Disorder</th>
                  <th id="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mode of Inheritance</th>
                  <th id="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Biochemical Testing / Other</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">18q deletion syndrome</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Most often <italic toggle="yes">de novo</italic> deletion; may be inherited</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Chromosome analysis for 18q microdeletion involving <italic toggle="yes">MBP</italic></td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="apbd" document-type="chapter">Adult polyglucosan body disease</related-object> (APBD)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">GBE1</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Histopathologic examination of muscle, nerve, axillary skin: pathologic polyglucosan accumulation</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="ags" document-type="chapter">Aicardi-Gouti&#x000e8;res syndrome</related-object> (AGS)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Usually AR; may be AD</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">TREX1<break/>RNASEH2A<break/>RNASEH2B<break/>RNASEH2C<break/>SAMHD1<break/>ADAR</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">CSF analysis: lymphocytosis, &#x02191;&#x000a0;interferon-&#x003b1;, &#x02191;&#x000a0;pterins</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">GFAP</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="lad-ad" document-type="chapter">AD adult-onset leukodystrophy</related-object> (ADLD)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">LMNB1</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cerebroretinal microangiopathy w/calcifications &#x00026; cysts (CRMCC)&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Likely AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Clinical &#x00026; neuroradiologic features</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <related-object link-type="booklink" source-id="gene" document-id="canavan" document-type="chapter">Canavan disease</related-object>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">ASPA</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">In urine, plasma, CSF, &#x00026; amniotic fluid: &#x02191;&#x000a0;N-acetylaspartic acid in urine<break/>In skin fibroblasts: deficient aspartoacylase enzyme activity</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="ctx" document-type="chapter">Cerebrotendinous xanthomatosis</related-object> (CTX)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">CYP27A1</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">In plasma &#x00026; CSF: &#x02191;&#x000a0;cholestanol concentration, &#x02193;&#x000a0;chenodeoxycholic acid<break/>In bile, urine, plasma: &#x02191;&#x000a0;concentration bile alcohols &#x00026; glyconjugates<break/>In fibroblasts, liver, leukocytes: &#x02193;&#x000a0;sterol 27-hydroxylase activity</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="cach" document-type="chapter">Childhood ataxia w/CNS hypomyelination / vanishing white matter</related-object> (CACH/VWM)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">EIF2B1-5</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="issd" document-type="chapter">Free sialic acid storage disorders</related-object>&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">SLC17A5</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">In urine, fibroblast, lysosomes: &#x02191;&#x000a0;free sialic acid</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Fucosidosis</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">FUCA1</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">On urinary oligosaccharide assay: &#x02191;&#x000a0;fucose-containing glycoconjugates<break/>In leukocytes or fibroblasts: deficient &#x003b1;-fucosidase activity</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="tubb4a-leuk" document-type="chapter">Hypomyelination w/atrophy of the basal ganglia &#x00026; cerebellum</related-object> (H-ABC)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Likely AD</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">TUBB4A</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Clinical &#x00026; neuroradiologic features</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="hypo-mcc" document-type="chapter">Hypomyelination and congenital cataract</related-object> (HCC)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">FAM126A</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <related-object link-type="booklink" source-id="gene" document-id="krabbe" document-type="chapter">Krabbe disease</related-object>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">GALC</italic><break/>See footnote 4</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">In leukocytes or fibroblasts: deficient galactocerebrosidase activity</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">L-2-hydroxyglutaric aciduria</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">L2HGDH</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">In plasma, urine, CSF: &#x02191;&#x000a0;concentration of L-2-hydroxyglutaric acid (and lysine)</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="lbsl" document-type="chapter">Leukoencephalopathy w/brain stem &#x00026; spinal cord involvement &#x00026; lactate elevation</related-object> (LBSL)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">DARS2</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Leukoencephalopathy w/thalamus and brain stem involvement &#x00026; lactate elevation (LTBL)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">EARS2</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="mlc" document-type="chapter">Megalencephalic leukodystrophy w/subcortical cysts</related-object> (MLC)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">MLC1<break/>HEPACAM (MLC2)</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">Metachromatic leukodystrophy</related-object> (MLD)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">ARSA</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">In leukocytes, fibroblasts: &#x02193;&#x000a0;arylsulfatase A activity<break/>In urine: &#x02191;&#x000a0;sulfatides</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">PSAP</italic>-related MLD&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">PSAP</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">In leukocytes, fibroblasts: normal arylsulfatase A activity<break/>In urine: &#x02191;&#x000a0;sulfatides</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Multiple sulfatase deficiency (MSD)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">SUMF1</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02193;&#x000a0;activity of other sulfatases<break/>In urine: &#x02191;&#x000a0;mucopolisaccharides, &#x02191;&#x000a0;urinary sulfatides</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="hdls" document-type="chapter">Hereditary diffuse leukoencephalopathy w/spheroids</related-object> (HDLS)&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">CSF1R</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Oculodentodigital dysplasia (ODDD)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Usually AD; may be AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">GJA1</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="pmd" document-type="chapter">Pelizaeus-Merzbacher disease</related-object> (PMD)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">PLP1</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Pelizaeus-Merzbacher-like disease 1 (PMLD1)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">GJC2</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="pbd" document-type="chapter">Peroxisome biogenesis disorders, Zellweger syndrome spectrum</related-object> (PBD, ZSS)&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><italic toggle="yes">PEX</italic> genes</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Plasma VLCFA, phytanic &#x00026; pristanic acid, plasma &#x00026; urine concentration of pipecolic acid &#x00026; bile acids aid to distinguish different forms of peroxisomal disorders</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="pol3-leuk" document-type="chapter">Pol III-related leukodystrophies</related-object>&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">POLR3A<break/>POLR3B</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">RNAse T2-deficient leukoencephalopathy</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">RNASET2</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">Single-enzyme deficiencies of peroxisomal fatty acid beta oxidation&#x000a0;<sup>9</sup></td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" rowspan="3" valign="middle" align="left" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Dibifunctional protein deficiency: <italic toggle="yes">HSD17B4</italic></td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" rowspan="3" valign="middle" align="left" colspan="1">Plasma VLCFA, phytanic &#x00026; pristanic acid, plasma &#x00026; urine concentration of pipecolic acid &#x00026; bile acids aid to distinguish different forms of peroxisomal disorders</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Peroxisomal acyl-CoA-oxidase deficiency: <italic toggle="yes">ACOX1</italic></td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" colspan="1" align="left" scope="col" rowspan="1">SCPx deficiency: <italic toggle="yes">SCP2</italic></td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Sj&#x000f6;gren-Larsson syndrome</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">ALDH3A2</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">In urine: abnormal metabolites of leukotriene B4 <break/>In cultured skin fibroblasts, leukocytes: deficiency of fatty aldehyde dehydrogenase activity (FALDH) and/or of fatty alcohol:NAD oxidoreductase (FAO)</td>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">SOX10</italic>-associated disorders</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">SOX10</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object> (X-ALD)</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <italic toggle="yes">ABCD1</italic>
                  </td>
                  <td headers="hd_h_leukodys-ov.T.leukodystrophies_meeting_s_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">On plasma VLCFA assay: C26:0, &#x02191;&#x000a0;ratio of C24:0 to C22:0, &#x02191;&#x000a0;ratio of C26:0 to C22:0</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>AD = autosomal dominant</p>
              </fn>
              <fn>
                <p>AR = autosomal recessive</p>
              </fn>
              <fn>
                <p>XL = X-linked</p>
              </fn>
              <fn>
                <p>VLCFA = very long-chain fatty acid</p>
              </fn>
              <fn>
                <p>Disorders listed in alphabetical order; naming as per <italic toggle="yes">GeneReviews</italic></p>
              </fn>
              <fn id="leukodys-ov.TF.1.1">
                <label>1. </label>
                <p>Genetic testing is available for many of these genes.</p>
              </fn>
              <fn id="leukodys-ov.TF.1.2">
                <label>2. </label>
                <p>This disorder now appears to be distinct from Coats plus caused by pathogenic variants in <italic toggle="yes">CTC1</italic>, encoding conserved telomere maintenance component 1.</p>
              </fn>
              <fn id="leukodys-ov.TF.1.3">
                <label>3. </label>
                <p>Includes Salla disease; infantile sialic acid storage disease, intermediate form</p>
              </fn>
              <fn id="leukodys-ov.TF.1.4">
                <label>4. </label>
                <p>Defects in <italic toggle="yes">PSAP</italic> causing a deficiency in the activator protein of SapA-d essential for the action of GALC have been reported.</p>
              </fn>
              <fn id="leukodys-ov.TF.1.5">
                <label>5. </label>
                <p>Pathogenic variants in <italic toggle="yes">PSAP</italic> result in deficiency in SapB-d, an activator protein essential for ARSA activity.</p>
              </fn>
              <fn id="leukodys-ov.TF.1.6">
                <label>6. </label>
                <p>Also known as adult-onset leukodystrophy w/ neuroaxonal spheroids &#x00026; pigmented glia; may include hereditary diffuse; pigmentary</p>
              </fn>
              <fn>
                <p>type of orthochromatic leukodystrophy w/pigmented glia (POLD)</p>
              </fn>
              <fn id="leukodys-ov.TF.1.7">
                <label>7. </label>
                <p>Includes neonatal adrenoleukodystrophy; infantile Refsum disease</p>
              </fn>
              <fn id="leukodys-ov.TF.1.8">
                <label>8. </label>
                <p>Includes hypomyelination, hypodontia, hypogonadotropic hypogonadism (4H syndrome); ataxia, delayed dentition, and hypomyelination (ADDH); tremor-ataxia with central hypomyelination (TACH); leukodystrophy with oligodontia (LO); and hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum (HCAHC).</p>
              </fn>
              <fn id="leukodys-ov.TF.1.9">
                <label>9. </label>
                <p>Includes D-bifunctional protein (DBP) deficiency; sterol carrier protein-2 (SCPx) deficiency; peroxisomal acyl-CoA-oxidase deficiency</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="leukodys-ov.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="leukodys-ov.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Leukodystrophies with an identified genetic cause may be inherited in an autosomal dominant manner, an autosomal recessive manner, or an X-linked recessive manner; other inheritance patterns may be identified as more genetic causes of leukodystrophy are discovered.</p>
          <p>If a proband has a specific syndrome associated with a leukodystrophy, counseling for that condition is indicated.</p>
        </sec>
        <sec id="leukodys-ov.Risk_to_Family_Members__Auto">
          <title>Risk to Family Members &#x02014; Autosomal Dominant Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed as having autosomal dominant leukodystrophy have an affected parent, although occasionally the family history is negative.</p>
            </list-item>
            <list-item>
              <p>Family history may appear to be negative because of early death of a parent, failure to recognize autosomal dominant leukodystrophy in family members, late onset in a parent, reduced penetrance of the mutated allele in an asymptomatic parent, or a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to sibs depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If one of the proband's parents has a mutated allele, the risk to the sibs of inheriting the mutated allele is 50%.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Individuals with autosomal dominant leukodystrophy have a 50% chance of transmitting the mutated allele to each child.</p>
        </sec>
        <sec id="leukodys-ov.Risk_to_Family_Members__Auto_1">
          <title>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents are obligate heterozygotes and therefore carry a single copy of a pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of a proband has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the chance of his/her being a carrier is 2/3.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> All offspring are obligate carriers.</p>
        </sec>
        <sec id="leukodys-ov.Risk_to_Family_Members__XLin">
          <title>Risk to Family Members &#x02014; X-Linked Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have the disease nor will he be a carrier of the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Women who have an affected son and another affected male relative are obligate heterozygotes. These females may be affected, sometimes with only certain features of the disease, or with milder symptoms. Note: If a woman has more than one affected child and no other affected relatives and if the pathogenic variant cannot be detected in her leukocyte DNA, she has germline mosaicism. Rarely, the unaffected father of an affected female may have germline mosaicism.</p>
            </list-item>
            <list-item>
              <p>A mother of an affected female who has a pathogenic variant may have favorably skewed X-chromosome inactivation that results in her being unaffected or mildly affected.</p>
            </list-item>
            <list-item>
              <p>An individual who is the only affected family member (i.e., a simplex case) may have a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to sib depends on the carrier status of the mother:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the mother of the proband has a pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Male sibs who inherit the variant will be affected; female sibs who inherit the variant will be carriers and will usually not be affected.</p>
            </list-item>
            <list-item>
              <p>If the proband represents a simplex case (i.e., a single occurrence in a family) and if the pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal germline mosaicism.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Daughters of an affected male will be obligate carriers and may or may not be affected; none of his sons will be affected.</p>
            </list-item>
            <list-item>
              <p>Each child of an affected female has a 50% chance of inheriting the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Because of possible skewing of X-chromosome inactivation, variable phenotypes in females are possible.</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the genetic status of the proband&#x02019;s parents.</p>
        </sec>
        <sec id="leukodys-ov.Related_Genetic_Counseling_I">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="leukodys-ov.Prenatal_Testing_and_Preimpl">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for leukodystrophy are possible.</p>
        </sec>
      </sec>
      <sec id="leukodys-ov.Resources">
        <title>Resources</title>
      </sec>
      <sec id="leukodys-ov.Management">
        <title>Management</title>
        <sec id="leukodys-ov.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Although the underlying mechanisms of leukodystrophies are diverse, many manifestations are similar across this group of disorders. In the great majority of cases, primary treatment is not possible, but management of symptoms can improve the comfort and care of individuals with these complex disorders.</p>
          <p>Ideally, the child or adult with a leukodystrophy is managed in a multidisciplinary setting by providers experienced in the care of persons with a leukodystrophy.</p>
          <p><bold>Spasticity.</bold> Pharmacologic agents are used to manage muscle tone and block neuronal signaling to muscle (chemodenervaton). Intensive physical therapy is used to improve mobility and function.</p>
          <p><bold>Extrapyramidal manifestations.</bold> Dystonia and dyskinesias may cause significant disability; pharmacologic treatment may result in significant functional improvement.</p>
          <p><bold>Ataxia.</bold> No specific treatment of ataxia exists, although rehabilitative measures can be of great assistance.</p>
          <p><bold>Seizures.</bold> Seizures should be treated with typical anticonvulsants and are rarely refractory, except on occasion at the end of life.</p>
          <p><bold>Cognitive developmental delay/encephalopathy.</bold> It is important to advocate for persons with a leukodystrophy in school or at work to avoid limitations related to their motor disabilities. Augmentative communication may be used to address speech deficits. Accommodations for cognitive delays and fine motor disabilities should be used as needed.</p>
          <p><bold>Orthopedic.</bold> Attention should be given to the prevention and treatment of orthopedic problems, such as hip dislocation and scoliosis.</p>
          <p><bold>Feeding.</bold> Swallowing dysfunction and pulmonary problems resulting from the increased risk of aspiration are common as the disease progresses. Decreased nutritional intake and failure to thrive may also occur. The decision to place a gastrostomy tube for nutrition is based on the overall health status of the individual, expected disease course, and family and patient wishes.</p>
        </sec>
        <sec id="leukodys-ov.Prevention_of_Primary_Manife">
          <title>Prevention of Primary Manifestations</title>
          <p>Primary disease manifestations can be prevented in a few of the leukodystrophies: in <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object>, <related-object link-type="booklink" source-id="gene" document-id="krabbe" document-type="chapter">Krabbe disease</related-object>, and <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">metachromatic leukodystrophy</related-object>, for example, hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation (BMT) may be beneficial if performed early in the disease course. Patients with these disorders should be referred to specialized centers for consideration of HSCT or BMT [<xref ref-type="bibr" rid="leukodys-ov.REF.eichler.2009.1893">Eichler et al 2009</xref>].</p>
        </sec>
        <sec id="leukodys-ov.Surveillance">
          <title>Surveillance</title>
          <p>Standard surveillance includes the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Routine measurement of weight and height to assess growth and nutritional status</p>
            </list-item>
            <list-item>
              <p>Physical examination and/or serial x-rays of the hips and spine to monitor for orthopedic complications</p>
            </list-item>
            <list-item>
              <p>Routine history re signs and symptoms of seizures</p>
            </list-item>
          </list>
          <p>Certain disorders require specialized surveillance, for example monitoring for the development of hydrocephalus in <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object>.</p>
        </sec>
        <sec id="leukodys-ov.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>In a number of leukodystrophies anecdotal evidence suggests episodic worsening of manifestations with mild head injuries and infection. While this has been clearly documented only for <related-object link-type="booklink" source-id="gene" document-id="cach" document-type="chapter">childhood ataxia with central nervous system hypomyelination/vanishing white matter</related-object>, it appears prudent to avoid these triggers when possible.</p>
        </sec>
        <sec id="leukodys-ov.Evaluation_of_Relatives_at_R">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="leukodys-ov.Genetic_Counseling">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="leukodys-ov.Therapies_Under_Investigatio">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="leukodys-ov.References">
        <title>References</title>
        <sec id="leukodys-ov.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="leukodys-ov.Literature_Cited.reflist0">
            <ref id="leukodys-ov.REF.bezman.2001.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bezman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>GV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kass</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                </person-group>
                <article-title>Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening.</article-title>
                <source>Ann Neurol.</source>
                <year>2001</year>
                <volume>49</volume>
                <fpage>512</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11310629</pub-id>
              </element-citation>
            </ref>
            <ref id="leukodys-ov.REF.bonkowsky.2010.718">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonkowsky</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingston</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filloux</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mundorff</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srivastava</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The burden of inherited leukodystrophies in children.</article-title>
                <source>Neurology</source>
                <volume>75</volume>
                <fpage>718</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">20660364</pub-id>
              </element-citation>
            </ref>
            <ref id="leukodys-ov.REF.eichler.2009.1893">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eichler</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grodd</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grant</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sessa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biffi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bley</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlschuetter</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loes</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraegeloh-Mann</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Metachromatic leukodystrophy: a scoring system for brain MR imaging observations.</article-title>
                <source>AJNR Am J Neuroradiol</source>
                <volume>30</volume>
                <fpage>1893</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19797797</pub-id>
              </element-citation>
            </ref>
            <ref id="leukodys-ov.REF.heim.1997.475">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Heim</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claussen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conzelmann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e4;rtner</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harzer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunneman</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;hler</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurlemann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlsch&#x000fc;tter</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Leukodystrophy incidence in Germany.</article-title>
                <source>Am J Med Genet</source>
                <volume>71</volume>
                <fpage>475</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9286459</pub-id>
              </element-citation>
            </ref>
            <ref id="leukodys-ov.REF.schiffmann.2009.750">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Invited article: an MRI-based approach to the diagnosis of white matter disorders.</article-title>
                <source>Neurology</source>
                <volume>72</volume>
                <fpage>750</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19237705</pub-id>
              </element-citation>
            </ref>
            <ref id="leukodys-ov.REF.van_der_knaap.1999.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van der Knaap</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breiter</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naidu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hart</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valk</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach.</article-title>
                <source>Radiology</source>
                <volume>213</volume>
                <fpage>121</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">10540652</pub-id>
              </element-citation>
            </ref>
            <ref id="leukodys-ov.REF.van_der_knaap.2005">
              <mixed-citation publication-type="book">van der Knaap MS, Valk J. <italic toggle="yes">Magnetic Resonance of Myelination and Myelin Disorders</italic>. Berlin, Germany: Springer. 2005.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="leukodys-ov.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="leukodys-ov.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>6 February 2014 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>14 February 2012 (av) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="leukodys-ov.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Hypomyelinating leukodystrophy has T<sub>2</sub>-weighted hyperintensity (&#x02191;) and T<sub>1</sub>-weighted iso- (&#x02192;) or hyperintensity (&#x02191;) of affected white matter. Demyelinating leukodystrophy has T<sub>2</sub>-weighted hyperintensity (&#x02191;) and T<sub>1</sub>-weighted hypointensity (&#x02193;) of affected white matter.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leukodys-ov-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="leukodys-ov.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Hypomyelinating leukodystrophy &#x02013; patterns on MRIA&#x02192;B. Improvement of myelination over time in <related-object link-type="booklink" source-id="gene" document-id="thctd" document-type="chapter">MCT8-specific thyroid hormone cell transporter deficiency</related-object> seen in a male with documented <italic toggle="yes">SLC16A2</italic> (<italic toggle="yes">MCT8</italic>) pathogenic variants at age two years (A) and age 4.5 years (B)C. GM1 gangliosidosis with hypomyelination accompanied by early loss of white matter volumeD. Persistent and severe hypomyelination seen in a school-aged child with <related-object link-type="booklink" source-id="gene" document-id="pmd" document-type="chapter">Pelizaeus-Merzbacher disease</related-object>E. Cerebellar atrophy seen in <related-object link-type="booklink" source-id="gene" document-id="pol3-leuk" document-type="chapter"><italic toggle="yes">POLR3</italic>-related leukodystrophy</related-object> (4H syndrome); arrow indicates atrophy.F. Basal ganglia involvement seen in <related-object link-type="booklink" source-id="gene" document-id="tubb4a-leuk" document-type="chapter">H-ABC syndrome</related-object>; arrow indicates atrophy of the putamen, a classic finding in this disorder.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leukodys-ov-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="leukodys-ov.F3" orientation="portrait">
          <label>Figure 3. </label>
          <caption>
            <p>Confluent white matter lesions are extensive white matter abnormalities in significant portions of the brain, often affecting specific regions or tracts, although not necessarily perfectly symmetrically. Multifocal white matter lesions are more discrete, often asymmetric and involving a limited area.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leukodys-ov-Image003" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="leukodys-ov.F4" orientation="portrait">
          <label>Figure 4. </label>
          <caption>
            <p>Demyelinating leukodystrophy &#x02013; patterns on MRIA. Diffuse cerebral involvement in an individual with <related-object link-type="booklink" source-id="gene" document-id="mlc" document-type="chapter">megalencephalic leukodystrophy with subcortical cysts</related-object>B. Primarily frontal involvement in a child with <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object>; arrow indicates white matter abnormalities in the frontal region.C. Primarily parieto-occipital involvement in a child with <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object>; arrow indicates white matter abnormalities in the parieto-occipital region.D. Primarily temporal involvement in an individual with <related-object link-type="booklink" source-id="gene" document-id="ags" document-type="chapter">Aicardi-Gouti&#x000e8;res syndrome</related-object>; arrow indicates white matter abnormalities in the temporal region.E. Primarily subcortical involvement in <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Kearns-Sayre syndrome</related-object>; arrow indicates sparing of the white matter in the periventricular region.F. Primarily periventricular involvement in an individual with <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">metachromatic leukodystrophy</related-object>; subcortical fibers are spared; arrow indicates sparing of white matter in the subcortical region. G. Primarily brain stem involvement in an individual with <related-object link-type="booklink" source-id="gene" document-id="apbd" document-type="chapter">adult polyglucosan body disease</related-object> with heterogeneous involvement of the brain stem; arrow indicates white matter abnormalities in the brain stem.H. Primarily cerebellar and middle cerebellar peduncle involvement in an individual with <related-object link-type="booklink" source-id="gene" document-id="lad-ad" document-type="chapter">autosomal dominant adult-onset leukodystrophy</related-object> (ADLD); arrow indicates white matter abnormalities in the middle cerebellar peduncles. I. Large, asymmetric lesions in an individual with <related-object link-type="booklink" source-id="gene" document-id="hdls" document-type="chapter">hereditary diffuse leukoencephalopathy with spheroids</related-object> (HDLS); arrow indicates asymmetric white matter abnormalities in the frontal region.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leukodys-ov-Image004" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="leukodys-ov.F5" orientation="portrait">
          <label>Figure 5. </label>
          <caption>
            <p>Algorithm Part 1: Demyelinating and other conditionsAdapted from <xref ref-type="bibr" rid="leukodys-ov.REF.schiffmann.2009.750">Schiffmann &#x00026; van der Knaap [2009]</xref></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leukodys-ov-Image005" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="leukodys-ov.F6" orientation="portrait">
          <label>Figure 6. </label>
          <caption>
            <p>Algorithm Part 2: Hypomyelinating conditionsAdapted from <xref ref-type="bibr" rid="leukodys-ov.REF.schiffmann.2009.750">Schiffmann &#x00026; van der Knaap [2009]</xref></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leukodys-ov-Image006" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="leukodys-ov.F7" orientation="portrait">
          <label>Figure 7. </label>
          <caption>
            <p>Features associated with specific leukodystrophiesA. White matter rarefaction and cysts on FLAIR imaging in vanishing white matter disease; arrow indicates cystic rarefaction within abnormal white matter.B. Calcium deposits and hemosiderin deposits visible on CT in <related-object link-type="booklink" source-id="gene" document-id="ags" document-type="chapter">Aicardi-Gouti&#x000e8;res syndrome</related-object>; not easily distinguishable on MRI; arrow indicates basal ganglia calcifications.C. Contrast enhancement on T<sub>1</sub>-weighted imaging within abnormal white matter in <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object>; arrow indicates contrast enhancement in the abnormal white matter.D. Cortical gray matter lesions in <related-object link-type="booklink" source-id="gene" document-id="alpers" document-type="chapter"><italic toggle="yes">POLG</italic>-related disorders</related-object>; arrow indicates swollen appearance of the cortical mantle and loss of gray-white matter differentiation.E. Cerebellar abnormalities seen in the dentate nucleus in L-2-hydroxyglutaric aciduria; arrow indicates symmetric hyperintensity.F. Thinning of the corpus callosum (particularly of the genu) in <related-object link-type="booklink" source-id="gene" document-id="spg11" document-type="chapter">hereditary spastic paraplegia 11</related-object>; arrow indicates thin corpus callosum with anterior beaking typically seen in this disorder.G. Non-calcifying basal ganglia lesions in <related-object link-type="booklink" source-id="gene" document-id="alexander" document-type="chapter">Alexander disease</related-object>; arrow indicates hyperintense signal within the basal ganglia.H. Typical brain stem involvement in <related-object link-type="booklink" source-id="gene" document-id="lad-ad" document-type="chapter">AD adult-onset leukodystrophy</related-object> (ADLD); arrow indicates hyperintense lesions within the brain stem.I. Spinal cord involvement in <related-object link-type="booklink" source-id="gene" document-id="lbsl" document-type="chapter">LBSL</related-object>; arrow indicates hyperintense lesions within the spinal cord, affecting tracts longitudinally throughout the length of the visible cord.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leukodys-ov-Image007" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
